Jilin Tuohua Biotechnology

Jilin Tuohua Biotechnology is a Chinese biopharmaceutical company founded in 2010 that specializes in the development of cell-based therapies and regenerative medicine. The company's primary focus is on human umbilical cord mesenchymal stem cells (hUC-MSCs) for the treatment of inflammatory, fibrotic, and degenerative conditions, with lead programs in Phase 1/2 clinical trials for decompensated hepatitis B cirrhosis and acute respiratory distress syndrome (ARDS). Jilin Tuohua operates a comprehensive business model encompassing R&D, cell storage, and clinical translation, supported by a network of subsidiaries in Suzhou and Beijing. In addition to its stem cell pipeline, the company is exploring recombinant proteins, such as IL-18 binding proteins, and immune cell therapies for oncology and autoimmune indications.